Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Malignant ascites often has a profound impact on the quality of life of cancer patients.
Current treatments,including dietary, medical, and procedural are often temporary and
unsatisfactory options in patients approaching the end of life. Intraperitoneal bevacizumab
for the palliation of malignant ascites might be a novel choice for refractory malignant
ascites.